|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0008838,
umls-concept:C0008976,
umls-concept:C0024109,
umls-concept:C0078257,
umls-concept:C0205088,
umls-concept:C0205179,
umls-concept:C0246415,
umls-concept:C0278627,
umls-concept:C0282461,
umls-concept:C0442027,
umls-concept:C0684249,
umls-concept:C1253959,
umls-concept:C1274040,
umls-concept:C1708063,
umls-concept:C2348867
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2009-6-22
|
|
pubmed:abstractText |
The study compared the efficacy of a first-line treatment with day 1 i.v. vinorelbine (NVBiv) and day 8 oral vinorelbine (NVBo) versus docetaxel (DCT) in a cisplatin-based combination in advanced non-small-cell lung cancer, in terms of time to treatment failure (TTF), overall response, progression-free survival (PFS), overall survival (OS), tolerance and quality of life (QoL).
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
1569-8041
|
|
pubmed:author |
pubmed-author:AbrattRR,
pubmed-author:AitiniEE,
pubmed-author:CarteniGG,
pubmed-author:GatzemeierUU,
pubmed-author:GrodzkiTT,
pubmed-author:RiskaHH,
pubmed-author:RolskiJJ,
pubmed-author:SchneiderC PCP,
pubmed-author:TanE HEH,
pubmed-author:TsaiY HYH,
pubmed-author:ZatloukalPP
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
20
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1249-56
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:19276396-Administration, Oral,
pubmed-meshheading:19276396-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:19276396-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:19276396-Cisplatin,
pubmed-meshheading:19276396-Combined Modality Therapy,
pubmed-meshheading:19276396-Disease-Free Survival,
pubmed-meshheading:19276396-Drug Administration Schedule,
pubmed-meshheading:19276396-Female,
pubmed-meshheading:19276396-Follow-Up Studies,
pubmed-meshheading:19276396-Humans,
pubmed-meshheading:19276396-Infusions, Intravenous,
pubmed-meshheading:19276396-Kaplan-Meier Estimate,
pubmed-meshheading:19276396-Lung Neoplasms,
pubmed-meshheading:19276396-Male,
pubmed-meshheading:19276396-Prospective Studies,
pubmed-meshheading:19276396-Quality of Life,
pubmed-meshheading:19276396-Survival Analysis,
pubmed-meshheading:19276396-Taxoids,
pubmed-meshheading:19276396-Treatment Outcome,
pubmed-meshheading:19276396-Vinblastine
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Global Lung Oncology Branch trial 3 (GLOB3): final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung cancer.
|
|
pubmed:affiliation |
Department of Medical Oncology, Division of Clinical Trials and Epidemiological Sciences, National Cancer Centre, Singapore. tanenghuat123@gmail.com
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase III
|
